Search

Search Constraints

You searched for: Author/Creator Shaw, Alice T.

Search Results

22. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014. (January 2015)

24. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. (December 2022)

25. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse. (18th May 2022)

26. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (January 2020)

29. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non–small cell lung cancer treated with radiotherapy for brain metastases. (22nd July 2014)